Going concern
Filing comparison
Processa Pharmaceuticals, Inc. disclosed substantial doubt about its ability to continue as a going concern
Risk-factor language only → Substantial doubt about ability to continue as a going concern
… y within our control. Our plan to address this potential cash-settlement obligation is to obtain the requisite stockholder approval at a meeting expected to take place in the first quarter of 2027 and thereafter complete the conversion of the Series A Preferred Stock and delivery of the underlying common stock, subject to applicable beneficial ownership limitations. Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued. Use of Estimates In…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- filing body
- Prior filed
- 2026-08-14
- Prior form
- 10-Q
- Prior state
- risk_factor_only
- Prior state label
- Risk-factor language only
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.